BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 26125892)

  • 1. Expression and significance of S100P, CD147, and OCT4 in different prostate cancer tissue TNM stages.
    Wang Q; Zhang JG; Wang W
    Genet Mol Res; 2015 Jun; 14(2):6844-51. PubMed ID: 26125892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expression and significance of CD147 protein in prostate cancer].
    He HC; Han ZD; Dai QS; Zou J; Zhang Y; Zhang Z; Liang YX; Ye YK; Chen ZN; Zhong WD
    Zhonghua Yi Xue Za Zhi; 2009 Jul; 89(26):1844-6. PubMed ID: 19953931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer.
    Zhong WD; Han ZD; He HC; Bi XC; Dai QS; Zhu G; Ye YK; Liang YX; Qin WJ; Zhang Z; Zeng GH; Chen ZN
    Oncology; 2008; 75(3-4):230-6. PubMed ID: 18852494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and clinical significance of CD147 in genitourinary carcinomas.
    Han ZD; He HC; Bi XC; Qin WJ; Dai QS; Zou J; Ye YK; Liang YX; Zeng GH; Zhu G; Chen ZN; Zhong WD
    J Surg Res; 2010 May; 160(2):260-7. PubMed ID: 19286191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [IDENTIFICATION OF A NEW DIAGNOSTIC MARKERS OF PROSTATIC CANCER, USING NOTI-MICROCHIPS].
    Vozianov SO; Kashuba VI; Grygorenko VM; Gordiyuk VV; Danylets RO; Bondarenko YM; Vikarchuk MV
    Klin Khir; 2016 Apr; (4):54-7. PubMed ID: 27434957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpressions of RACK1 and CD147 associated with poor prognosis in stage T1 pulmonary adenocarcinoma.
    Zhong X; Li M; Nie B; Wu F; Zhang L; Wang E; Han Y
    Ann Surg Oncol; 2013 Mar; 20(3):1044-52. PubMed ID: 22592183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated nuclear S100P expression is associated with poor survival in early breast cancer patients.
    Maciejczyk A; Łacko A; Ekiert M; Jagoda E; Wysocka T; Matkowski R; Hałoń A; Györffy B; Lage H; Surowiak P
    Histol Histopathol; 2013 Apr; 28(4):513-24. PubMed ID: 23364898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
    Zhao Z; Liu J; Li S; Shen W
    Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical expression of interleukin-2 receptor and interleukin-6 in patients with prostate cancer and benign prostatic hyperplasia: association with asymptomatic inflammatory prostatitis NIH category IV.
    Engelhardt PF; Seklehner S; Brustmann H; Lusuardi L; Riedl CR
    Scand J Urol; 2015 Apr; 49(2):120-6. PubMed ID: 25363611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.
    Higgins JP; Kaygusuz G; Wang L; Montgomery K; Mason V; Zhu SX; Marinelli RJ; Presti JC; van de Rijn M; Brooks JD
    Am J Surg Pathol; 2007 May; 31(5):673-80. PubMed ID: 17460449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression levels of heat shock protein 27 and cellular FLICE-like inhibitory protein in prostate cancer correlate with Gleason score sum and pathologic stage.
    Lee SW; Cho JM; Cho HJ; Kang JY; Kim EK; Yoo TK
    Korean J Urol; 2015 Jul; 56(7):505-14. PubMed ID: 26175869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of mRNA, Protein, and Urinary Nucleic Acid Levels of S100A8 and S100A9 between Prostate Cancer and BPH.
    Yun SJ; Yan C; Jeong P; Kang HW; Kim YH; Kim EA; Lee OJ; Kim WT; Moon SK; Kim IY; Choi YH; Kim WJ
    Ann Surg Oncol; 2015 Jul; 22(7):2439-45. PubMed ID: 25348783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OCT-4, an embryonic stem cell marker, is highly expressed in bladder cancer.
    Atlasi Y; Mowla SJ; Ziaee SA; Bahrami AR
    Int J Cancer; 2007 Apr; 120(7):1598-602. PubMed ID: 17205510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. c-met proto-oncogene expression in benign and malignant human prostate tissues.
    Pisters LL; Troncoso P; Zhau HE; Li W; von Eschenbach AC; Chung LW
    J Urol; 1995 Jul; 154(1):293-8. PubMed ID: 7539865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stromal response to prostate cancer: nanotechnology-based detection of thioredoxin-interacting protein partners distinguishes prostate cancer associated stroma from that of benign prostatic hyperplasia.
    Singer E; Linehan J; Babilonia G; Imam SA; Smith D; Loera S; Wilson T; Smith S
    PLoS One; 2013; 8(6):e60562. PubMed ID: 23762225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy.
    Grupp K; Höhne TS; Prien K; Hube-Magg C; Tsourlakis MC; Sirma H; Pham T; Heinzer H; Graefen M; Michl U; Simon R; Wilczak W; Izbicki J; Sauter G; Minner S; Schlomm T; Steurer S
    Exp Mol Pathol; 2013 Oct; 95(2):227-34. PubMed ID: 23948277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S100P predicts prognosis and drug resistance in gastric cancer.
    Ge F; Wang C; Wang W; Wu B
    Int J Biol Markers; 2013 Dec; 28(4):e387-92. PubMed ID: 23722300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions.
    Henrique R; Jerónimo C; Hoque MO; Carvalho AL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
    DNA Cell Biol; 2005 Apr; 24(4):264-9. PubMed ID: 15812243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression patterns of potential therapeutic targets in prostate cancer.
    Zellweger T; Ninck C; Bloch M; Mirlacher M; Koivisto PA; Helin HJ; Mihatsch MJ; Gasser TC; Bubendorf L
    Int J Cancer; 2005 Feb; 113(4):619-28. PubMed ID: 15472903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional evidence implicating S100P in prostate cancer progression.
    Basu GD; Azorsa DO; Kiefer JA; Rojas AM; Tuzmen S; Barrett MT; Trent JM; Kallioniemi O; Mousses S
    Int J Cancer; 2008 Jul; 123(2):330-339. PubMed ID: 18452169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.